Stock Code: 600299 Stock Name: Adisseo No: 2026-051

Bluestar Adisseo Company

Announcement of Main Operating Data for Q3 2026

The board of directors and all directors guarantee that this announcement does not contain any false statement, misleading statement or material omission, and assume legal liability for the authenticity, accuracy and integrity of this announcement.

In accordance with *Shanghai Stock Exchange Industrial Information Disclosure Guidance No. 14- Food Manufacturing Industry*, here present the operating data for the half year of 2026:

I. Main Operating Data for Q3 2026

Analysis by product

Unit: Yuan Currency: RMB

Operating Revenue			
By product	Q3 2026	Q3 2025	Changes in comparison with the same period of last year (%)
Performance products	4,434,508,161	3,275,298,626	35.39
Specialty products	1,139,398,660	1,143,676,282	-0.37
Total	5,573,906,821	4,418,974,908	26.14

Safety is and will remain Adisseo's priority. Continuous excellent safety results have been achieved in Q3 2026 with TRIR landed at 0.065 and process safety on good track.

In Q3 2026, Adisseo recorded a double-digit revenue growth (+26% yoy, CNY5.57 billion)/QoQ (+5%), with gross profit increased (+59% yoy, CNY1.88 billion)/QoQ (+15%), driven by:

Q3 2026 is an outstanding quarter for the methionine business with best revenue record thanks to

- Pricing management thanks to global sales & marketing network and its capability to manage pricing fluctuation vs cost increase in different regions
- Robust volume growth
- High plant reliability in Nanjing plant and Roussillon plant
- Positive contribution from by-product
- Offsetting negative impact arising from raw materials and disruption in European plants due to transportation restriction

Vitamins business is under pressure but is being managed in the most agile and lean manner:

- For vitamin A: rebound on volume but with depressed market price. However, VA cost optimization project is well on track
- Resilient results on VE and Portfolio and is expected to be improved thanks to the optimizing of the sourcing strategy

In Q3 2026, Specialties business delivered better-than-market revenue growth at constant FX level:

- All Species with healthy growth momentum: 1) continuous growth in Monogastric supported by good market trend for poultry 2) outstanding Aqua performance, 3) considerable growth in Ruminants despite fierce competition environment, and 4) tangible progress achieved in pet business.
- Product line wise, double-digit growth in both Feed Integrity& Quality line (Palatability and Mycotoxin Management) and in Animal Resilience line led by Alterion, Selisseo and Farm Care, and continued double-digit growth in Protected Amino-acid
- Innovation effect contributes to the acceleration with more to come thanks to the successful launch of new products in 2026
- Good progress on profitability and strategy execution: price increases in main products, profitability improvement enhancement plans and fixed costs management

One-China Strategy recorded strong double-digit revenue growth in Q3 2026 thanks to:

- Continued strong growth in methionine
- Solid growth in specialties business, a success of "local for local" strategy, mainly contributed by strong growth in monogastric driven by local customized products in feed integrity and animal resilience as well as rebounding ruminant business thanks to the recovering dairy market in China
- Nanjing plant is running at a high speed with excellent reliability.

In Q3 2026, EBITDA ratio landed at 26%, a strong improvement of +8ppt compared with last year.

Analysis by sales channel

Unit: Yuan Currency: RMB

Operating Revenue			
By product	Q3 2026	Q3 2025	Changes in comparison with the same period of last year (%)
Direct Sales	4,639,116,646	3,916,672,100	18.45
Distribution Channel	934,790,175	502,302,808	86.10
Total	5,573,906,821	4,418,974,908	26.14

Analysis by region

Unit: Yuan Currency: RMB

Operating Revenue

By region	Q3 2026	Q3 2025	Changes in comparison with the same period of last year (%)
Domestic*	1,117,911,860	791,213,410	41.29
Overseas*	4,455,994,961	3,627,761,498	22.83
Total	5,573,906,821	4,418,974,908	26.14

*Domestic means operating revenue in China. Overseas means operating revenue outside China.

Adisseo achieved broad-based revenue growth across its major geographic markets in the third quarter. Thanks to the global set-up of the company, the positive impact from the agile management of geopolitical tension in the Middle East has been reflected in the results.

II. Changes in Dealers/Distributors for Q3 2026

By region	Number of dealers/distributors at the end of the reporting period	Additions during the reporting period	Deletions during the reporting period
Domestic	27	5	-
Overseas	139	10	-
Total	166	15	-

It is hereby announced.

Board of Directors of Bluestar Adisseo Company
30th October 2026

(In case of discrepancies between the English version and the Chinese version of this announcement, the Chinese version, officially published and disclosed, shall prevail.)